Ad
OTLK Quote Trading Chart Outlook Therapeutics Inc.
home / stock / otlk / otlk quote
Quote | Outlook Therapeutics Inc. (NASDAQ:OTLK)
| Last: | $1.54 |
|---|---|
| Change Percent: | -0.64% |
| Open: | $1.58 |
| Close: | $1.54 |
| High: | $1.65 |
| Low: | $1.5205 |
| Volume: | 676,957 |
| Last Trade Date Time: | 12/12/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
OTLK Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $1.54 | $1.58 | $1.54 | $1.65 | $1.5205 | 676,957 | 12-12-2024 |
| $1.57 | $1.6 | $1.57 | $1.6194 | $1.5 | 787,933 | 12-11-2024 |
| $1.61 | $1.74 | $1.61 | $1.8498 | $1.595 | 862,006 | 12-10-2024 |
| $1.7 | $1.53 | $1.7 | $1.8795 | $1.53 | 2,069,950 | 12-09-2024 |
| $1.52 | $1.56 | $1.52 | $1.5799 | $1.47 | 977,127 | 12-06-2024 |
| $1.47 | $1.68 | $1.47 | $1.68 | $1.45 | 1,812,639 | 12-05-2024 |
| $1.66 | $1.85 | $1.66 | $1.85 | $1.59 | 2,413,529 | 12-04-2024 |
| $1.805 | $1.98 | $1.805 | $2.05 | $1.8 | 1,827,794 | 12-03-2024 |
| $2.03 | $2.07 | $2.03 | $2.42 | $1.98 | 5,495,621 | 12-02-2024 |
| $2.05 | $1.7 | $2.05 | $2.09 | $1.6899 | 7,846,472 | 11-29-2024 |
| $1.7 | $0.981 | $1.7 | $2.21 | $0.87 | 62,276,313 | 11-28-2024 |
| $1.7 | $0.981 | $1.7 | $2.21 | $0.87 | 62,276,313 | 11-27-2024 |
| $4.89 | $4.94 | $4.89 | $5.15 | $4.84 | 434,175 | 11-26-2024 |
| $4.93 | $5.09 | $4.93 | $5.18 | $4.92 | 570,079 | 11-25-2024 |
| $5.03 | $5.14 | $5.03 | $5.24 | $4.99 | 330,677 | 11-22-2024 |
| $5.13 | $5.22 | $5.13 | $5.29 | $5.06 | 215,399 | 11-21-2024 |
| $5.28 | $5.2 | $5.28 | $5.44 | $5.17 | 145,169 | 11-20-2024 |
| $5.23 | $5.13 | $5.23 | $5.285 | $5.03 | 174,707 | 11-19-2024 |
| $5.155 | $5.42 | $5.155 | $5.45 | $5.14 | 128,230 | 11-18-2024 |
| $5.41 | $5.53 | $5.41 | $5.53 | $5.22 | 285,214 | 11-15-2024 |
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Company Name:
OTLK Stock Symbol:
NASDAQ Market:
Outlook Therapeutics Inc. Website:
Ad
-
First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 40,000 ne...
-
ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of...
-
2024-11-29 06:30:01 ET BTIG analyst issues BUY recommendation for OTLK on November 29, 2024 11:02AM ET. The previous analyst recommendation was Buy. OTLK was trading at $1.7591 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...